Los Angeles Capital Management LLC Purchases Shares of 6,396 Soleno Therapeutics, Inc. $SLNO

Los Angeles Capital Management LLC purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 6,396 shares of the company’s stock, valued at approximately $536,000.

Other large investors have also recently modified their holdings of the company. Bank of New York Mellon Corp lifted its position in Soleno Therapeutics by 345.0% during the first quarter. Bank of New York Mellon Corp now owns 302,664 shares of the company’s stock valued at $21,625,000 after acquiring an additional 234,649 shares during the last quarter. Arizona State Retirement System increased its position in shares of Soleno Therapeutics by 9.2% during the first quarter. Arizona State Retirement System now owns 7,380 shares of the company’s stock worth $527,000 after purchasing an additional 620 shares in the last quarter. Mutual of America Capital Management LLC purchased a new stake in shares of Soleno Therapeutics during the 1st quarter valued at $5,186,000. Victory Capital Management Inc. acquired a new stake in shares of Soleno Therapeutics in the 1st quarter worth $288,000. Finally, Atle Fund Management AB grew its stake in Soleno Therapeutics by 19.9% during the 1st quarter. Atle Fund Management AB now owns 37,098 shares of the company’s stock worth $2,651,000 after buying an additional 6,158 shares during the last quarter. Institutional investors own 97.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on SLNO. Guggenheim reiterated a “buy” rating and issued a $106.00 price target on shares of Soleno Therapeutics in a research note on Wednesday, August 27th. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective (up from $100.00) on shares of Soleno Therapeutics in a research report on Monday, August 18th. Lifesci Capital upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $114.50.

Soleno Therapeutics Trading Up 4.4%

Shares of NASDAQ:SLNO opened at $49.42 on Friday. The company has a quick ratio of 15.01, a current ratio of 15.13 and a debt-to-equity ratio of 0.21. Soleno Therapeutics, Inc. has a 52-week low of $41.50 and a 52-week high of $90.32. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of -11.94 and a beta of -2.92. The business has a 50-day moving average price of $60.27 and a 200-day moving average price of $72.04.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.39. The firm had revenue of $66.02 million during the quarter, compared to analysts’ expectations of $47.46 million. Equities analysts predict that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.